SEOM clinical guideline for the management of cutaneous melanoma (2020)

Majem, Margarita; Manzano, José Luís; Márquez-Rodas, Iván; Mujika, Karmele; Muñoz‐Couselo, Eva; Pérez-Ruiz, Elísabeth; Cruz‐Merino, Luis de la; Espinosa, Enrique; González‐Cao, María; Berrocal, A.

doi:10.1007/s12094-020-02539-9

Cited by 25 publications

(15 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Next, 76 full-text articles were assessed for eligibility, of them again were excluded (justifications are provided in Fig. 1 ), leaving 29 articles 14 , 15 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 for appraisal with the AGREE II tool. A summary of the characteristics of the articles appraised in this review is presented in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool

et al. 2022

View full text Add to dashboard Cite

Background The evidence base behind new melanoma treatments is rapidly accumulating. This is not necessarily reflected in current guidance. A recent UK-based expert consensus statement, published in JPRAS, has called for updates to the widely accepted 2015 National Institute for Health and Care Excellence (NICE) guideline for melanoma (NG14). We aimed to compare the quality of NG14 to all other melanoma guidelines published since. Methods We conducted a systematic search of PubMed, Medline, and online clinical practice guideline databases to identify melanoma guidelines published between 29th July 2015 and 23rd August 2021 providing recommendations for adjuvant treatment, radiotherapy, surgical management, or follow-up care. Three authors independently assessed the quality of identified guidelines using the Appraisal of Guidelines for Research & Evaluation Instrument II (AGREE II) assessment tool, which measures six domains of guideline development. Inter-rater reliability was assessed by Kendall's coefficient of concordance (W). Results Twenty-nine guidelines were included and appraised with excellent concordance (Kendall's W for overall guideline score 0.88, p<0.001). Overall, melanoma guidelines scored highly in the domains of ‘Scope and purpose’ and ‘Clarity of presentation’, but poorly in the ‘Applicability’ domain. The NICE guideline on melanoma (NG14) achieved the best overall scores. Conclusion Melanoma treatment has advanced since NG14 was published, however, the NICE melanoma guideline is of higher quality than more recent alternatives. The planned update of NG14 in 2022 is in demand.

show abstract

Section: Resultsmentioning

confidence: 99%

Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The genetic landscape of melanoma has been described in the last years but is still a field in a continuous evolution [20,21]. Melanoma genetic markers play a role not only in melanoma susceptibility (familial melanoma, see below), initiation, and progression but also in prognosis and therapy [22,23]. In fact, most cases of melanoma are diagnosed at an early stage, when surgical excision can be curative.…”

Section: Introductionmentioning

confidence: 99%

“…For high-risk and metastatic melanoma patients, determination of BRAF status (see below) drives their management. Patients harboring the BRAF mutation may receive first-line targeted therapies (i.e., dabrafenib plus trametinib, vemurafenib plus cobimetinib, and encorafenib plus binimetinib) in both metastatic and adiuvant settings, while immunotherapy is the first line in wild-type patients [22,24,25].…”

Section: Introductionmentioning

confidence: 99%

“…Melanoma is one of the most sensitive tumors to immune modulation. Immune checkpoint inhibitors (ICIs) against cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) have dramatically changed the management of both unresectable and metastatic melanoma as well as those at high risk for recurrence after resection [22,24,25].…”

Section: Introductionmentioning

confidence: 99%

“…Radiation therapy may have a palliative role for symptomatic localized areas of disease. Radiation therapy, especially stereotactic radiosurgery, may be particularly important for patients with brain metastases [22,24,25].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dermoscopic Criteria, Histopathological Correlates and Genetic Findings of Thin Melanoma on Non-Volar Skin

Massone

Hofman-Wellenhof

Chiodi

et al. 2021

Genes

View full text Add to dashboard Cite

Dermoscopy is a non-invasive, in vivo technique that allows the visualization of subsurface skin structures in the epidermis, at the dermoepidermal junction, and in the upper dermis. Dermoscopy brought a new dimension in evaluating melanocytic skin neoplasms (MSN) also representing a link between clinical and pathologic examination of any MSN. However, histopathology remains the gold standard in diagnosing MSN. Dermoscopic–pathologic correlation enhances the level of quality of MSN diagnosis and increases the level of confidence of pathologists. Melanoma is one of the most genetically predisposed among all cancers in humans. The genetic landscape of melanoma has been described in the last years but is still a field in continuous evolution. Melanoma genetic markers play a role not only in melanoma susceptibility, initiation, and progression but also in prognosis and therapeutic decisions. Several studies described the dermoscopic specific criteria and predictors for melanoma and their histopathologic correlates, but only a few studies investigated the correlation among dermoscopy, pathology, and genetic of MSN. The aim of this work is to review the published data about dermoscopic features of melanoma, their histopathological correlates with regards also to genetic alterations. Particularly, this review will focus on low-CSD (cumulative sun damage) melanoma or superficial spreading melanoma, high-CSD melanoma, and nevus-associated melanoma.

show abstract

The Value of Contrast‐Enhanced Ultrasound in the Detection of Sentinel Lymph Nodes in Malignant Melanoma

Deng

et al. 2022

J of Ultrasound Medicine

View full text Add to dashboard Cite

Objective To evaluate the location and characterization value of contrast‐enhanced ultrasound (CEUS) in the detection of sentinel lymph nodes (SLNs) in malignant melanoma. Methods SLNs and the lymph node network were tracked by subcutaneous injection of ultrasonic contrast agent around the tumor and preoperative localization, and qualitative analyses were performed. The SLNs were also detected by the intraoperative subcutaneous injection of carbon nanoparticles, and the findings were compared with lymph nodes located by CEUS. The accuracy of the preoperative lymph node identification was evaluated by the results of postoperative pathology, which served as the gold standard of detection. Results In 47 patients with malignant melanoma, the mean number of SLNs detected by CEUS was 1.72 ± 0.10, while that by carbon nanoparticle administration it was 1.79 ± 1.07 (P = .371 > .05). Seven cases of lymph node metastasis were detected by CEUS, with a sensitivity of 70.0%, specificity of 97.3%, positive predictive value of 87.5%, negative predictive value of 92.3%, and accuracy of 91.5%. There was high consistency between the findings of CEUS and pathology in differentiating benign and malignant lymph nodes (kappa = 0.726, χ2 = 25.243, P < .001). Conclusions CEUS can localize and differentiate SLNs in malignant melanoma, and thus, may potentially guide clinical treatment in the future.

show abstract

SEOM clinical guideline for the management of cutaneous melanoma (2020)

Cited by 25 publications

References 71 publications

Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool

Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool

Dermoscopic Criteria, Histopathological Correlates and Genetic Findings of Thin Melanoma on Non-Volar Skin

The Value of Contrast‐Enhanced Ultrasound in the Detection of Sentinel Lymph Nodes in Malignant Melanoma

Contact Info

Product

Resources

About